Status:
COMPLETED
Identification the Cause of Cerebral Infarction in Patients With Cancer
Lead Sponsor:
Samsung Medical Center
Conditions:
Cryptogenic Embolic Stroke
Active Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Although there has been increasing interest in the association between cancer and cerebrovascular disease, the underlying pathophysiology of stroke in cancer patients is still not fully understood. Th...
Detailed Description
Patients with cryptogenic embolic stroke will be prospectively enrolled and categorized into two groups according to the presence of active cancer: cryptogenic embolic stroke with active cancer (cance...
Eligibility Criteria
Inclusion
- Subjects with acute ischemic stroke who presented within 7 days from symptom onset
- Subjects who had embolic infarction outside the perforator territory revealed by diffusion-weighted imaging
- Subjects with undetermined cause of stroke despite of initial evaluation including electrocardiogram and brain imaging upon admission
- Subjects who performed brain magnetic resonance image (MRI) and MR angiography (MRA), cardiac work-ups (12-lead electrocardiography, transthoracic and/or transesophageal echocardiography with injection of agitated saline (or agitated saline transcranial Doppler monitoring), and 24-hour Holter and/or telemonitoring)
- Subjects with informed consent
Exclusion
- Subjects with single subcortical infarction
- Subjects with primary brain tumor
- Inability to perform comprehensive studies
- Refusal or withdrawal of the consent
Key Trial Info
Start Date :
August 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2018
Estimated Enrollment :
118 Patients enrolled
Trial Details
Trial ID
NCT02212496
Start Date
August 1 2014
End Date
March 1 2018
Last Update
July 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea, 135710